You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAzelastine
Accession NumberDB00972  (APRD00813)
TypeSmall Molecule
GroupsApproved
DescriptionAzelastine, a phthalazine derivative, is an antihistamine and mast cell stabilizer available as a nasal spray for hay fever and as eye drops for allergic conjunctivitis. Azelastine is also available as a combination product of azelastine hydrochloride and fluticasone propionate called Dymista™. Dymista™ is indicated in patient over 12 years old for symptomatic relief of seasonal allergic rhinitis.
Structure
Thumb
Synonyms
4-(P-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-phthalazinone
Azelastina
Azelastinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Astelinspray, metered137 ug/1nasalPhysicians Total Care, Inc.2004-05-25Not applicableUs
Astelinspray, metered137 ug/1nasalMeda Pharmaceuticals Inc.1996-11-15Not applicableUs
Asteprospray, metered205.5 ug/1nasalMeda Pharmaceuticals Inc.2009-10-12Not applicableUs
Azelastine Hydrochloridespray, metered205.5 ug/1nasalWallace Pharmaceuticals Inc.2015-04-01Not applicableUs
Azelastine Hydrochloridespray, metered137 ug/1nasalWallace Pharmaceuticals Inc.2010-07-01Not applicableUs
Azelastine Hydrochloridesolution/ drops.5 mg/mLintraocularWallace Pharmaceuticals Inc.2010-10-01Not applicableUs
Azelastine Hydrochloridespray, metered205.5 ug/1nasalPerrigo New York Inc2015-04-09Not applicableUs
Optivarsolution/ drops.5 mg/mLintraocularMeda Pharmaceuticals Inc.2000-05-22Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Azelastine HCl Nasalspray205.5 ug/1nasalPerrigo New York Inc2014-05-09Not applicableUs
Azelastine Hydrochloridespray, metered137 ug/1nasalApotex Corp.2010-03-01Not applicableUs
Azelastine Hydrochloridespray, metered137 ug/1nasalRoxane Laboratories, Inc.2014-10-27Not applicableUs
Azelastine Hydrochloridespray, metered137 ug/.137mLnasalBreckenridge Pharmaceutical, Inc.2015-07-29Not applicableUs
Azelastine Hydrochloridespray, metered205.5 ug/1nasalApotex Corp.2014-07-07Not applicableUs
Azelastine Hydrochloridespray, metered137 ug/1nasalPhysicians Total Care, Inc.2011-06-28Not applicableUs
Azelastine Hydrochloridesolution/ drops.5 mg/mLintraocularSandoz Inc2013-03-21Not applicableUs
Azelastine Hydrochloridespray, metered137 ug/1nasalSun Pharma Global FZE2012-05-24Not applicableUs
Azelastine Hydrochloridesolution/ drops.5 mg/mLintraocularApotex Corp.2009-12-01Not applicableUs
Azelastine Hydrochloridespray, metered137 ug/.137mLnasalAv Kare, Inc.2016-04-01Not applicableUs
Azelastine Hydrochloridesolution/ drops.5 mg/mLintraocularSun Pharma Global FZE2010-05-31Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
DymistaMeda Pharmaceuticals Inc.
Salts
Name/CASStructureProperties
Azelastine Hydrochloride
79307-93-0
Thumb
  • InChI Key: YEJAJYAHJQIWNU-UHFFFAOYNA-N
  • Monoisotopic Mass: 417.137467851
  • Average Mass: 418.359
DBSALT000013
Categories
UNIIZQI909440X
CAS number58581-89-8
WeightAverage: 381.898
Monoisotopic: 381.160790112
Chemical FormulaC22H24ClN3O
InChI KeyInChIKey=MBUVEWMHONZEQD-UHFFFAOYSA-N
InChI
InChI=1S/C22H24ClN3O/c1-25-13-4-5-18(12-14-25)26-22(27)20-7-3-2-6-19(20)21(24-26)15-16-8-10-17(23)11-9-16/h2-3,6-11,18H,4-5,12-15H2,1H3
IUPAC Name
4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)-1,2-dihydrophthalazin-1-one
SMILES
CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=CC=CC=C2C1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phthalazinones. These are compounds containing a phthalazine bearing a ketone group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassNaphthyridines
Sub ClassPhthalazines
Direct ParentPhthalazinones
Alternative Parents
Substituents
  • Phthalazinone
  • Pyridazinone
  • Halobenzene
  • Chlorobenzene
  • Azepane
  • Benzenoid
  • Pyridazine
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Lactam
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the symptomatic treatment of seasonal allergic rhinitis and non-allergic rhinitis, as well as symptomatic relief of ocular itching associated with allergic conjunctivitis.
PharmacodynamicsAzelastine is a relatively selective histamine H1 antagonist, which inhibits the release of histamine and other mediators from cells (e.g. mast cells) involved in the allergic response. It has some affinity to H2 receptors. Based on in vitro studies using human cell lines, inhibition of other mediators involved in allergic reactions (e.g. leukotrienes and PAF) has been demonstrated with azelastine. Azelastine may also inhibit the accumulation and degranulation of eosinophils at the site of allergic inflammation.
Mechanism of actionAzelastine competes with histamine for the H1-receptor sites on effector cells and acts as an antagonist by inhibiting the release of histamine and other mediators involved in the allergic response.
Related Articles
AbsorptionAbsorption of azelastine following ocular administration was relatively low. Systemic bioavailability is approximately 40% after nasal administration.
Volume of distribution
  • 14.5 L/kg
Protein bindingIn-vitro studies in human plasma indicate that the plasma protein binding of azelastine and N-desmethylazelastine are approximately 88% and 97%, respectively.
Metabolism

Azelastine hydrochloride is oxidatively metabolized to the principal metabolite, N-desmethylazelastine, by the cytochrome P450 enzyme system, however the exact cytochrome P450 isoenzyme involved has not been determined. The major metabolite, desmethylazelastine, also has H1-receptor antagonist activity.

SubstrateEnzymesProduct
Azelastine
DesmethylazelastineDetails
Route of eliminationApproximately 75% of an oral dose of radiolabeled azelastine hydrochloride was excreted in the feces with less than 10% as unchanged azelastine. Azelastine hydrochloride is oxidatively metabolized to the principal metabolite, N-desmethylazelastine, by the cytochrome P450 enzyme system.
Half lifeElimination half-life (based on intravenous and oral administration) is 22 hours. Elimination half-life of the active metabolite, desmethylazelastine, is 54 hours (after oral administration of azelastine).
Clearance
  • 0.5 L/h/kg [symptomatic patients]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.982
Caco-2 permeable-0.5102
P-glycoprotein substrateSubstrate0.7034
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.9563
Renal organic cation transporterInhibitor0.6812
CYP450 2C9 substrateNon-substrate0.7501
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.8204
CYP450 1A2 substrateInhibitor0.6371
CYP450 2C9 inhibitorNon-inhibitor0.8114
CYP450 2D6 inhibitorNon-inhibitor0.568
CYP450 2C19 inhibitorNon-inhibitor0.6934
CYP450 3A4 inhibitorNon-inhibitor0.5902
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7266
Ames testNon AMES toxic0.6567
CarcinogenicityNon-carcinogens0.878
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.0597 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7885
hERG inhibition (predictor II)Inhibitor0.7391
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Apotex inc richmond hill
  • Sun pharma global fze
  • Meda pharmaceuticals inc
  • Meda pharmaceuticals meda pharmaceuticals inc
  • Apotex inc
  • Meda pharmaceuticals
Packagers
Dosage forms
FormRouteStrength
Spray, meterednasal137 ug/1
Spray, meterednasal205.5 ug/1
Spraynasal205.5 ug/1
Spray, meterednasal137 ug/.137mL
Spray, meterednasal
Spray, metered dosenasal
Solution/ dropsintraocular.5 mg/mL
Prices
Unit descriptionCostUnit
Optivar 0.05% Solution 6ml Bottle120.26USD bottle
Astelin 137 mcg/spray Solution 30ml Bottle117.27USD bottle
Azelastine HCl 0.05% Solution 6ml Bottle108.23USD bottle
Optivar 0.05% drops19.27USD ml
Azelastine hcl 0.05% drops17.35USD ml
Astelin 137 mcg nasal spray3.71USD ml
Astepro 137 mcg nasal spray3.61USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5164194 No1994-05-012011-05-01Us
US8071073 No2008-06-042028-06-04Us
US8163723 No2003-08-292023-08-29Us
US8168620 No2006-02-242026-02-24Us
US8518919 No2005-11-222025-11-22Us
US9259428 No2003-06-132023-06-13Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point225 °C (hydrochloride salt)Not Available
water solubilitySparingly soluble (hydrochloride salt)Not Available
logP4.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0092 mg/mLALOGPS
logP3.81ALOGPS
logP4.04ChemAxon
logS-4.6ALOGPS
pKa (Strongest Basic)8.88ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area35.91 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity110.52 m3·mol-1ChemAxon
Polarizability41.54 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Yutaka Morita, Noritoshi Koyama, Shigemitsu Ohsawa, “Methods employing stable preparation containing azelastine hydrochloride.” U.S. Patent US6117864, issued December, 1990.

US6117864
General References
  1. Horak F: Effectiveness of twice daily azelastine nasal spray in patients with seasonal allergic rhinitis. Ther Clin Risk Manag. 2008 Oct;4(5):1009-22. [PubMed:19209282 ]
  2. Bernstein JA: Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. Curr Med Res Opin. 2007 Oct;23(10):2441-52. [PubMed:17723160 ]
External Links
ATC CodesR06AX19S01GX07R01AC03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (17.5 KB)
MSDSDownload (36.8 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Azelastine.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Azelastine.
7-Nitroindazole7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Azelastine is combined with 7-Nitroindazole.
AbciximabAzelastine may increase the anticoagulant activities of Abciximab.
AbciximabAbciximab may increase the antiplatelet activities of Azelastine.
AbirateroneThe serum concentration of Azelastine can be increased when it is combined with Abiraterone.
AcebutololAzelastine may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Azelastine is combined with Aceclofenac.
AcenocoumarolAzelastine may increase the anticoagulant activities of Acenocoumarol.
AcepromazineAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AcepromazineThe risk or severity of adverse effects can be increased when Azelastine is combined with Acepromazine.
AceprometazineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AceprometazineThe risk or severity of adverse effects can be increased when Azelastine is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Azelastine.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Azelastine.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Azelastine.
adipiplonadipiplon may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
adipiplonThe risk or severity of adverse effects can be increased when Azelastine is combined with adipiplon.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Azelastine.
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AgomelatineThe risk or severity of adverse effects can be increased when Azelastine is combined with Agomelatine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Azelastine.
Alendronic acidThe risk or severity of adverse effects can be increased when Azelastine is combined with Alendronic acid.
AlfaxaloneAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Azelastine is combined with Alfaxalone.
AlfentanilAlfentanil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AlfentanilThe risk or severity of adverse effects can be increased when Azelastine is combined with Alfentanil.
AliskirenAzelastine may decrease the antihypertensive activities of Aliskiren.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Azelastine.
AlphacetylmethadolAlphacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Azelastine is combined with Alphacetylmethadol.
AlprazolamAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AlprazolamThe risk or severity of adverse effects can be increased when Azelastine is combined with Alprazolam.
AlprenololAzelastine may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Azelastine.
AlprostadilAlprostadil may increase the antiplatelet activities of Azelastine.
AlteplaseAzelastine may increase the anticoagulant activities of Alteplase.
ALX-0081Azelastine may increase the anticoagulant activities of ALX-0081.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Azelastine.
AmikacinAzelastine may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideAzelastine may decrease the antihypertensive activities of Amiloride.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Azelastine is combined with Aminosalicylic Acid.
AmiodaroneThe metabolism of Azelastine can be decreased when combined with Amiodarone.
AmisulprideAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AmisulprideThe risk or severity of adverse effects can be increased when Azelastine is combined with Amisulpride.
AmitriptylineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Azelastine.
AmobarbitalAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AmobarbitalThe risk or severity of adverse effects can be increased when Azelastine is combined with Amobarbital.
AmoxapineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AmoxapineThe risk or severity of adverse effects can be increased when Azelastine is combined with Amoxapine.
AmperozideAmperozide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AmperozideThe risk or severity of adverse effects can be increased when Azelastine is combined with Amperozide.
AmphetamineAmphetamine may decrease the sedative activities of Azelastine.
AnagrelideAzelastine may increase the anticoagulant activities of Anagrelide.
AnagrelideAnagrelide may increase the antiplatelet activities of Azelastine.
AncrodAzelastine may increase the anticoagulant activities of Ancrod.
AnistreplaseAzelastine may increase the anticoagulant activities of Anistreplase.
AntipyrineThe risk or severity of adverse effects can be increased when Azelastine is combined with Antipyrine.
Antithrombin III humanAzelastine may increase the anticoagulant activities of Antithrombin III human.
ApixabanAzelastine may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Azelastine is combined with Apremilast.
AprepitantThe serum concentration of Azelastine can be increased when it is combined with Aprepitant.
ArdeparinAzelastine may increase the anticoagulant activities of Ardeparin.
ArgatrobanAzelastine may increase the anticoagulant activities of Argatroban.
ArgatrobanArgatroban may increase the antiplatelet activities of Azelastine.
AripiprazoleAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AripiprazoleThe risk or severity of adverse effects can be increased when Azelastine is combined with Aripiprazole.
ArmodafinilThe metabolism of Azelastine can be decreased when combined with Armodafinil.
ArotinololAzelastine may decrease the antihypertensive activities of Arotinolol.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Azelastine.
ArtemetherThe metabolism of Azelastine can be decreased when combined with Artemether.
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Azelastine resulting in a loss in efficacy.
ArticaineArticaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ArticaineThe risk or severity of adverse effects can be increased when Azelastine is combined with Articaine.
AsenapineAsenapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AsenapineThe risk or severity of adverse effects can be increased when Azelastine is combined with Asenapine.
AstaxanthinAzelastine may increase the anticoagulant activities of Astaxanthin.
AtazanavirThe metabolism of Azelastine can be decreased when combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Azelastine.
AtenololAzelastine may decrease the antihypertensive activities of Atenolol.
AtomoxetineThe metabolism of Azelastine can be decreased when combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Azelastine.
AzaperoneAzaperone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzaperoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Azaperone.
AzapropazoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Azapropazone.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Azelastine.
AzithromycinThe metabolism of Azelastine can be decreased when combined with Azithromycin.
BaclofenBaclofen may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenThe risk or severity of adverse effects can be increased when Azelastine is combined with Baclofen.
BalsalazideAzelastine may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Azelastine.
BarbitalBarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BarbitalThe risk or severity of adverse effects can be increased when Azelastine is combined with Barbital.
BatroxobinAzelastine may increase the anticoagulant activities of Batroxobin.
BecaplerminAzelastine may increase the anticoagulant activities of Becaplermin.
BefunololAzelastine may decrease the antihypertensive activities of Befunolol.
BemiparinAzelastine may increase the anticoagulant activities of Bemiparin.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Azelastine.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Azelastine.
BenoxaprofenThe risk or severity of adverse effects can be increased when Azelastine is combined with Benoxaprofen.
BenzocaineBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BenzocaineThe risk or severity of adverse effects can be increased when Azelastine is combined with Benzocaine.
BenzphetamineBenzphetamine may decrease the sedative activities of Azelastine.
Benzyl alcoholBenzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Azelastine is combined with Benzyl alcohol.
Benzylpenicilloyl PolylysineAzelastine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BeraprostAzelastine may increase the anticoagulant activities of Beraprost.
BeraprostBeraprost may increase the antiplatelet activities of Azelastine.
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Azelastine.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Azelastine.
BetaxololAzelastine may decrease the antihypertensive activities of Betaxolol.
BetaxololThe metabolism of Azelastine can be decreased when combined with Betaxolol.
BevantololAzelastine may decrease the antihypertensive activities of Bevantolol.
BexaroteneThe serum concentration of Azelastine can be decreased when it is combined with Bexarotene.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Azelastine.
BisoprololAzelastine may decrease the antihypertensive activities of Bisoprolol.
BivalirudinAzelastine may increase the anticoagulant activities of Bivalirudin.
BoceprevirThe metabolism of Azelastine can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Azelastine.
BopindololAzelastine may decrease the antihypertensive activities of Bopindolol.
BortezomibThe metabolism of Azelastine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Azelastine can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Azelastine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Azelastine.
BrexpiprazoleBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Azelastine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BrimonidineThe risk or severity of adverse effects can be increased when Azelastine is combined with Brimonidine.
BromazepamBromazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BromazepamThe risk or severity of adverse effects can be increased when Azelastine is combined with Bromazepam.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Azelastine.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Azelastine.
BrompheniramineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BrompheniramineThe risk or severity of adverse effects can be increased when Azelastine is combined with Brompheniramine.
BrotizolamBrotizolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BrotizolamThe risk or severity of adverse effects can be increased when Azelastine is combined with Brotizolam.
BufuralolAzelastine may decrease the antihypertensive activities of Bufuralol.
BumetanideAzelastine may decrease the diuretic activities of Bumetanide.
BupivacaineBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BupivacaineThe risk or severity of adverse effects can be increased when Azelastine is combined with Bupivacaine.
BupranololAzelastine may decrease the antihypertensive activities of Bupranolol.
BuprenorphineBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BuprenorphineThe risk or severity of adverse effects can be increased when Azelastine is combined with Buprenorphine.
BupropionThe metabolism of Azelastine can be decreased when combined with Bupropion.
BuspironeBuspirone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BuspironeThe risk or severity of adverse effects can be increased when Azelastine is combined with Buspirone.
ButabarbitalButabarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ButabarbitalThe risk or severity of adverse effects can be increased when Azelastine is combined with Butabarbital.
ButacaineButacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ButacaineThe risk or severity of adverse effects can be increased when Azelastine is combined with Butacaine.
ButalbitalButalbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ButalbitalThe risk or severity of adverse effects can be increased when Azelastine is combined with Butalbital.
ButambenButamben may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ButambenThe risk or severity of adverse effects can be increased when Azelastine is combined with Butamben.
ButethalButethal may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ButethalThe risk or severity of adverse effects can be increased when Azelastine is combined with Butethal.
ButorphanolButorphanol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ButorphanolThe risk or severity of adverse effects can be increased when Azelastine is combined with Butorphanol.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Azelastine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Azelastine.
CaffeineThe metabolism of Azelastine can be decreased when combined with Caffeine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Azelastine.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Azelastine.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Azelastine.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Azelastine.
CangrelorAzelastine may increase the anticoagulant activities of Cangrelor.
CangrelorCangrelor may increase the antiplatelet activities of Azelastine.
CapecitabineThe metabolism of Azelastine can be decreased when combined with Capecitabine.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Azelastine.
CarbamazepineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Azelastine.
CarbinoxamineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Azelastine is combined with Carbinoxamine.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Azelastine.
CarfentanilCarfentanil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
CarfentanilThe risk or severity of adverse effects can be increased when Azelastine is combined with Carfentanil.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Azelastine.
CarisoprodolCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
CarisoprodolThe risk or severity of adverse effects can be increased when Azelastine is combined with Carisoprodol.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Azelastine.
CarteololAzelastine may decrease the antihypertensive activities of Carteolol.
CarvedilolAzelastine may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Azelastine is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Azelastine.
CeliprololAzelastine may decrease the antihypertensive activities of Celiprolol.
CeritinibThe serum concentration of Azelastine can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Azelastine.
CertoparinAzelastine may increase the anticoagulant activities of Certoparin.
CetirizineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
CetirizineThe risk or severity of adverse effects can be increased when Azelastine is combined with Cetirizine.
Chloral hydrateChloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Azelastine is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Azelastine can be decreased when combined with Chloramphenicol.
ChlordiazepoxideChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Azelastine is combined with Chlordiazepoxide.
ChlormezanoneChlormezanone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Chlormezanone.
ChloroprocaineChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Azelastine is combined with Chloroprocaine.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Azelastine.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Azelastine.
ChlorphenamineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Azelastine is combined with Chlorphenamine.
ChlorphentermineChlorphentermine may decrease the sedative activities of Azelastine.
ChlorpromazineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Azelastine.
ChlorprothixeneChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Azelastine is combined with Chlorprothixene.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Azelastine.
ChlorzoxazoneChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Azelastine can be decreased when combined with Cholecalciferol.
CholestyramineCholestyramine can cause a decrease in the absorption of Azelastine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Azelastine.
CilostazolAzelastine may increase the anticoagulant activities of Cilostazol.
CilostazolCilostazol may increase the antiplatelet activities of Azelastine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Azelastine.
CimetidineThe metabolism of Azelastine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Azelastine can be decreased when combined with Cinacalcet.
CinchocaineCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
CinchocaineThe risk or severity of adverse effects can be increased when Azelastine is combined with Cinchocaine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Azelastine.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Azelastine.
CitalopramThe risk or severity of adverse effects can be increased when Azelastine is combined with Citalopram.
CitalopramThe metabolism of Azelastine can be decreased when combined with Citalopram.
Citric AcidAzelastine may increase the anticoagulant activities of Citric Acid.
ClarithromycinThe metabolism of Azelastine can be decreased when combined with Clarithromycin.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Azelastine.
ClemastineClemastine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ClemastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Clemastine.
ClidiniumClidinium may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ClidiniumThe risk or severity of adverse effects can be increased when Azelastine is combined with Clidinium.
ClobazamClobazam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Azelastine.
ClodronateThe risk or severity of adverse effects can be increased when Azelastine is combined with Clodronate.
clomethiazoleclomethiazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
clomethiazoleThe risk or severity of adverse effects can be increased when Azelastine is combined with clomethiazole.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Azelastine.
ClomipramineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ClomipramineThe risk or severity of adverse effects can be increased when Azelastine is combined with Clomipramine.
ClonazepamClonazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ClonazepamThe risk or severity of adverse effects can be increased when Azelastine is combined with Clonazepam.
ClonidineClonidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Azelastine.
ClonixinThe risk or severity of adverse effects can be increased when Azelastine is combined with Clonixin.
ClopidogrelAzelastine may increase the anticoagulant activities of Clopidogrel.
ClopidogrelClopidogrel may increase the antiplatelet activities of Azelastine.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Azelastine.
ClorazepateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ClorazepateThe risk or severity of adverse effects can be increased when Azelastine is combined with Clorazepate.
ClotrimazoleThe metabolism of Azelastine can be decreased when combined with Clotrimazole.
ClozapineClozapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Azelastine.
CobicistatThe serum concentration of Azelastine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Azelastine.
CocaineCocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
CocaineThe risk or severity of adverse effects can be increased when Azelastine is combined with Cocaine.
CodeineCodeine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
CodeineThe risk or severity of adverse effects can be increased when Azelastine is combined with Codeine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Azelastine.
ColesevelamColesevelam can cause a decrease in the absorption of Azelastine resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Azelastine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CollagenaseThe risk or severity of adverse effects can be increased when Azelastine is combined with Collagenase.
ConivaptanThe serum concentration of Azelastine can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Azelastine.
CrizotinibThe metabolism of Azelastine can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Azelastine.
CyclizineCyclizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
CyclizineThe risk or severity of adverse effects can be increased when Azelastine is combined with Cyclizine.
CyclobenzaprineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Azelastine is combined with Cyclobenzaprine.
CyclosporineThe metabolism of Azelastine can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Azelastine.
CyproheptadineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
CyproheptadineThe risk or severity of adverse effects can be increased when Azelastine is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Azelastine can be decreased when it is combined with Cyproterone acetate.
D-LimoneneThe risk or severity of adverse effects can be increased when Azelastine is combined with D-Limonene.
Dabigatran etexilateAzelastine may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Azelastine can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Azelastine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Azelastine.
DalteparinAzelastine may increase the anticoagulant activities of Dalteparin.
DanaparoidAzelastine may increase the anticoagulant activities of Danaparoid.
DantroleneDantrolene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DantroleneThe risk or severity of adverse effects can be increased when Azelastine is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Azelastine.
DapiprazoleDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DapiprazoleThe risk or severity of adverse effects can be increased when Azelastine is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Azelastine is combined with Dapoxetine.
DarifenacinThe metabolism of Azelastine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Azelastine can be increased when it is combined with Darunavir.
DasatinibDasatinib may increase the anticoagulant activities of Azelastine.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Azelastine.
DaunorubicinAzelastine may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Azelastine.
DeferasiroxThe serum concentration of Azelastine can be decreased when it is combined with Deferasirox.
DeferasiroxThe risk or severity of adverse effects can be increased when Azelastine is combined with Deferasirox.
DefibrotideAzelastine may increase the anticoagulant activities of Defibrotide.
DefibrotideDefibrotide may increase the antiplatelet activities of Azelastine.
DelavirdineThe metabolism of Azelastine can be decreased when combined with Delavirdine.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Azelastine is combined with Deoxycholic Acid.
deramciclanederamciclane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
deramciclaneThe risk or severity of adverse effects can be increased when Azelastine is combined with deramciclane.
DesfluraneDesflurane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DesfluraneThe risk or severity of adverse effects can be increased when Azelastine is combined with Desflurane.
DesipramineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DesipramineThe risk or severity of adverse effects can be increased when Azelastine is combined with Desipramine.
DesirudinAzelastine may increase the anticoagulant activities of Desirudin.
DesloratadineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DesloratadineThe risk or severity of adverse effects can be increased when Azelastine is combined with Desloratadine.
DesmopressinThe risk or severity of adverse effects can be increased when Azelastine is combined with Desmopressin.
DesmoteplaseAzelastine may increase the anticoagulant activities of Desmoteplase.
DetomidineDetomidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DetomidineThe risk or severity of adverse effects can be increased when Azelastine is combined with Detomidine.
DexamethasoneThe serum concentration of Azelastine can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Azelastine.
DexbrompheniramineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Azelastine is combined with Dexbrompheniramine.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Azelastine.
DexmedetomidineDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Azelastine is combined with Dexmedetomidine.
DextranAzelastine may increase the anticoagulant activities of Dextran.
Dextran 40Azelastine may increase the anticoagulant activities of Dextran 40.
Dextran 70Azelastine may increase the anticoagulant activities of Dextran 70.
Dextran 75Azelastine may increase the anticoagulant activities of Dextran 75.
DextroamphetamineDextroamphetamine may decrease the sedative activities of Azelastine.
DextromoramideDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DextromoramideThe risk or severity of adverse effects can be increased when Azelastine is combined with Dextromoramide.
DextropropoxypheneDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Azelastine is combined with Dextropropoxyphene.
DezocineDezocine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DezocineThe risk or severity of adverse effects can be increased when Azelastine is combined with Dezocine.
DiazepamDiazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Azelastine.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Azelastine.
DicoumarolAzelastine may increase the anticoagulant activities of Dicoumarol.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Azelastine.
DifenoxinDifenoxin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DifenoxinThe risk or severity of adverse effects can be increased when Azelastine is combined with Difenoxin.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Azelastine.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Azelastine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Azelastine.
DihydrocodeineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Azelastine is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Azelastine can be decreased when combined with Dihydroergotamine.
DihydroetorphineDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Azelastine is combined with Dihydroetorphine.
DihydromorphineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DihydromorphineThe risk or severity of adverse effects can be increased when Azelastine is combined with Dihydromorphine.
DihydrostreptomycinAzelastine may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Azelastine.
DiltiazemThe metabolism of Azelastine can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Azelastine.
DimenhydrinateDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Azelastine is combined with Dimenhydrinate.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Azelastine.
DiphenhydramineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Azelastine is combined with Diphenhydramine.
DiphenoxylateDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Azelastine is combined with Diphenoxylate.
DipyridamoleAzelastine may increase the anticoagulant activities of Dipyridamole.
DipyridamoleDipyridamole may increase the antiplatelet activities of Azelastine.
DitazoleAzelastine may increase the anticoagulant activities of Ditazole.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Azelastine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Azelastine.
DoramectinDoramectin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DoramectinThe risk or severity of adverse effects can be increased when Azelastine is combined with Doramectin.
DoxepinDoxepin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DoxepinThe risk or severity of adverse effects can be increased when Azelastine is combined with Doxepin.
DoxorubicinAzelastine may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DoxycyclineThe metabolism of Azelastine can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DoxylamineThe risk or severity of adverse effects can be increased when Azelastine is combined with Doxylamine.
DPDPEDPDPE may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DPDPEThe risk or severity of adverse effects can be increased when Azelastine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DronedaroneThe metabolism of Azelastine can be decreased when combined with Dronedarone.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DroperidolThe risk or severity of adverse effects can be increased when Azelastine is combined with Droperidol.
DrospirenoneAzelastine may increase the hyperkalemic activities of Drospirenone.
DrotebanolDrotebanol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DrotebanolThe risk or severity of adverse effects can be increased when Azelastine is combined with Drotebanol.
Drotrecogin alfaAzelastine may increase the anticoagulant activities of Drotrecogin alfa.
DroxicamThe risk or severity of adverse effects can be increased when Azelastine is combined with Droxicam.
DuloxetineThe metabolism of Azelastine can be decreased when combined with Duloxetine.
DyclonineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DyclonineThe risk or severity of adverse effects can be increased when Azelastine is combined with Dyclonine.
EcgonineEcgonine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
EcgonineThe risk or severity of adverse effects can be increased when Azelastine is combined with Ecgonine.
ECGONINE METHYL ESTERECGONINE METHYL ESTER may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Azelastine is combined with ECGONINE METHYL ESTER.
Edetic AcidAzelastine may increase the anticoagulant activities of Edetic Acid.
EdoxabanAzelastine may increase the anticoagulant activities of Edoxaban.
EfavirenzEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
EfavirenzThe risk or severity of adverse effects can be increased when Azelastine is combined with Efavirenz.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Azelastine.
EliglustatThe metabolism of Azelastine can be decreased when combined with Eliglustat.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Azelastine.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Azelastine.
EnfluraneEnflurane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
EnfluraneThe risk or severity of adverse effects can be increased when Azelastine is combined with Enflurane.
EnoxaparinAzelastine may increase the anticoagulant activities of Enoxaparin.
EntacaponeEntacapone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
EntacaponeThe risk or severity of adverse effects can be increased when Azelastine is combined with Entacapone.
EnzalutamideThe serum concentration of Azelastine can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Azelastine.
EpinastineEpinastine may increase the antiplatelet activities of Azelastine.
EpirizoleThe risk or severity of adverse effects can be increased when Azelastine is combined with Epirizole.
EpirubicinAzelastine may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneAzelastine may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Azelastine.
EpoprostenolEpoprostenol may increase the antiplatelet activities of Azelastine.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Azelastine.
EptifibatideAzelastine may increase the anticoagulant activities of Eptifibatide.
EptifibatideEptifibatide may increase the antiplatelet activities of Azelastine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Azelastine.
ErythromycinThe metabolism of Azelastine can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Azelastine.
EscitalopramThe risk or severity of adverse effects can be increased when Azelastine is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Azelastine can be decreased when it is combined with Eslicarbazepine acetate.
EsmololAzelastine may decrease the antihypertensive activities of Esmolol.
EsomeprazoleThe metabolism of Azelastine can be decreased when combined with Esomeprazole.
EstazolamEstazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
EstazolamThe risk or severity of adverse effects can be increased when Azelastine is combined with Estazolam.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Azelastine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Azelastine.
EstroneThe serum concentration of Estrone can be increased when it is combined with Azelastine.
EszopicloneEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
EszopicloneThe risk or severity of adverse effects can be increased when Azelastine is combined with Eszopiclone.
Etacrynic acidAzelastine may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Azelastine.
EthanolAzelastine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthchlorvynolEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Azelastine is combined with Ethchlorvynol.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Azelastine.
EthosuximideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
EthosuximideThe risk or severity of adverse effects can be increased when Azelastine is combined with Ethosuximide.
EthotoinEthotoin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
EthotoinThe risk or severity of adverse effects can be increased when Azelastine is combined with Ethotoin.
Ethyl biscoumacetateAzelastine may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Azelastine is combined with Ethyl carbamate.
Ethyl loflazepateEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Azelastine is combined with Ethyl loflazepate.
EthylmorphineEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
EthylmorphineThe risk or severity of adverse effects can be increased when Azelastine is combined with Ethylmorphine.
EtidocaineEtidocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
EtidocaineThe risk or severity of adverse effects can be increased when Azelastine is combined with Etidocaine.
Etidronic acidThe risk or severity of adverse effects can be increased when Azelastine is combined with Etidronic acid.
EtifoxineEtifoxine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
EtifoxineThe risk or severity of adverse effects can be increased when Azelastine is combined with Etifoxine.
EtizolamEtizolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
EtizolamThe risk or severity of adverse effects can be increased when Azelastine is combined with Etizolam.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Azelastine.
EtofenamateThe risk or severity of adverse effects can be increased when Azelastine is combined with Etofenamate.
EtomidateEtomidate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
EtomidateThe risk or severity of adverse effects can be increased when Azelastine is combined with Etomidate.
EtoperidoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Azelastine.
EtoricoxibThe risk or severity of adverse effects can be increased when Azelastine is combined with Etoricoxib.
EtorphineEtorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
EtorphineThe risk or severity of adverse effects can be increased when Azelastine is combined with Etorphine.
EtravirineThe serum concentration of Azelastine can be decreased when it is combined with Etravirine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Azelastine is combined with Evening primrose oil.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Azelastine.
exisulindThe risk or severity of adverse effects can be increased when Azelastine is combined with exisulind.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Azelastine.
EzogabineEzogabine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
EzogabineThe risk or severity of adverse effects can be increased when Azelastine is combined with Ezogabine.
FelbamateFelbamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
FelbamateThe risk or severity of adverse effects can be increased when Azelastine is combined with Felbamate.
FelodipineThe metabolism of Azelastine can be decreased when combined with Felodipine.
FenbufenThe risk or severity of adverse effects can be increased when Azelastine is combined with Fenbufen.
FencamfamineFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
FencamfamineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fenfluramine.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Azelastine.
FentanylFentanyl may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
FentanylThe risk or severity of adverse effects can be increased when Azelastine is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Azelastine.
FexofenadineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Azelastine.
FibrinolysinAzelastine may increase the anticoagulant activities of Fibrinolysin.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Azelastine.
FlibanserinFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
FlibanserinThe risk or severity of adverse effects can be increased when Azelastine is combined with Flibanserin.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Azelastine.
FloxuridineThe metabolism of Azelastine can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Azelastine can be decreased when combined with Fluconazole.
FludiazepamFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
FludiazepamThe risk or severity of adverse effects can be increased when Azelastine is combined with Fludiazepam.
FlunarizineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
FlunarizineThe risk or severity of adverse effects can be increased when Azelastine is combined with Flunarizine.
FlunitrazepamFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Azelastine is combined with Flunitrazepam.
FlunixinThe risk or severity of adverse effects can be increased when Azelastine is combined with Flunixin.
FluorouracilThe metabolism of Azelastine can be decreased when combined with Fluorouracil.
FluoxetineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluoxetine.
FluoxetineThe metabolism of Azelastine can be decreased when combined with Fluoxetine.
FlupentixolFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
FlupentixolThe risk or severity of adverse effects can be increased when Azelastine is combined with Flupentixol.
FluphenazineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
FluphenazineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluphenazine.
FlurazepamFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
FlurazepamThe risk or severity of adverse effects can be increased when Azelastine is combined with Flurazepam.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Azelastine.
FluspirileneFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
FluspirileneThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Azelastine.
Fluticasone PropionateFluticasone Propionate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Azelastine can be decreased when combined with Fluvastatin.
FluvoxamineFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
FluvoxamineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluvoxamine.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Azelastine.
Fondaparinux sodiumAzelastine may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Azelastine.
FosamprenavirThe metabolism of Azelastine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Azelastine can be increased when it is combined with Fosaprepitant.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Azelastine.
FosphenytoinFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
FosphenytoinThe risk or severity of adverse effects can be increased when Azelastine is combined with Fosphenytoin.
FospropofolFospropofol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
FospropofolThe risk or severity of adverse effects can be increased when Azelastine is combined with Fospropofol.
FramycetinAzelastine may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideAzelastine may decrease the diuretic activities of Furosemide.
Fusidic AcidThe serum concentration of Azelastine can be increased when it is combined with Fusidic Acid.
GabapentinGabapentin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
GabapentinThe risk or severity of adverse effects can be increased when Azelastine is combined with Gabapentin.
gabapentin enacarbilgabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Azelastine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Azelastine is combined with Gamma Hydroxybutyric Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Azelastine.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Azelastine.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Azelastine.
GemfibrozilThe metabolism of Azelastine can be decreased when combined with Gemfibrozil.
GentamicinAzelastine may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
GlucosamineGlucosamine may increase the antiplatelet activities of Azelastine.
GlutethimideGlutethimide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
GlutethimideThe risk or severity of adverse effects can be increased when Azelastine is combined with Glutethimide.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Azelastine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Azelastine.
GuanfacineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
GuanfacineThe risk or severity of adverse effects can be increased when Azelastine is combined with Guanfacine.
HalazepamHalazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
HalazepamThe risk or severity of adverse effects can be increased when Azelastine is combined with Halazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Azelastine is combined with Haloperidol.
HaloperidolHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
HalothaneHalothane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
HalothaneThe risk or severity of adverse effects can be increased when Azelastine is combined with Halothane.
HeparinAzelastine may increase the anticoagulant activities of Heparin.
HeroinHeroin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
HeroinThe risk or severity of adverse effects can be increased when Azelastine is combined with Heroin.
HexobarbitalHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
HexobarbitalThe risk or severity of adverse effects can be increased when Azelastine is combined with Hexobarbital.
HirulogAzelastine may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Azelastine is combined with HMPL-004.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Azelastine.
HydralazineAzelastine may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Azelastine.
HydrocodoneHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
HydrocodoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Hydrocodone.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Azelastine.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Azelastine.
HydromorphoneHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
HydromorphoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Hydromorphone.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Azelastine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
HydroxyzineThe risk or severity of adverse effects can be increased when Azelastine is combined with Hydroxyzine.
Hygromycin BAzelastine may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Azelastine is combined with Ibandronate.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Azelastine is combined with Ibritumomab tiuxetan.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Azelastine.
IbudilastAzelastine may increase the antiplatelet activities of Ibudilast.
IbuprofenThe risk or severity of adverse effects can be increased when Azelastine is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Azelastine is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Azelastine is combined with Icatibant.
Icosapent ethylAzelastine may increase the antiplatelet activities of Icosapent ethyl.
IdarubicinAzelastine may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IdelalisibThe serum concentration of Azelastine can be increased when it is combined with Idelalisib.
IfenprodilAzelastine may increase the antiplatelet activities of Ifenprodil.
IloperidoneIloperidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
IloperidoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Iloperidone.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Azelastine.
IloprostIloprost may increase the antiplatelet activities of Azelastine.
ImatinibThe metabolism of Azelastine can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Azelastine.
ImipramineImipramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Azelastine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Azelastine.
IndalpineThe risk or severity of adverse effects can be increased when Azelastine is combined with Indalpine.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Azelastine.
IndenololAzelastine may decrease the antihypertensive activities of Indenolol.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Azelastine.
IndinavirThe metabolism of Azelastine can be decreased when combined with Indinavir.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Azelastine.
IndoprofenThe risk or severity of adverse effects can be increased when Azelastine is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Azelastine.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Azelastine.
IsavuconazoniumThe metabolism of Azelastine can be decreased when combined with Isavuconazonium.
IsofluraneIsoflurane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
IsofluraneThe risk or severity of adverse effects can be increased when Azelastine is combined with Isoflurane.
IsoniazidThe metabolism of Azelastine can be decreased when combined with Isoniazid.
IsoxicamThe risk or severity of adverse effects can be increased when Azelastine is combined with Isoxicam.
IsradipineThe metabolism of Azelastine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Azelastine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Azelastine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Azelastine.
KanamycinAzelastine may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Kebuzone.
KetamineKetamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
KetamineThe risk or severity of adverse effects can be increased when Azelastine is combined with Ketamine.
KetazolamKetazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Azelastine.
KetobemidoneKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
KetobemidoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Ketobemidone.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Azelastine.
KetoconazoleThe metabolism of Azelastine can be decreased when combined with Ketoconazole.
KetoprofenThe risk or severity of adverse effects can be increased when Azelastine is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Azelastine.
LabetalolAzelastine may decrease the antihypertensive activities of Labetalol.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Azelastine.
LamotrigineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Azelastine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Azelastine.
LapatinibThe metabolism of Azelastine can be decreased when combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Azelastine.
LeflunomideThe risk or severity of adverse effects can be increased when Azelastine is combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Azelastine.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Azelastine.
LepirudinAzelastine may increase the anticoagulant activities of Lepirudin.
LevetiracetamLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Azelastine.
LevobunololAzelastine may decrease the antihypertensive activities of Levobunolol.
LevobupivacaineLevobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Azelastine is combined with Levobupivacaine.
LevocabastineLevocabastine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
LevocabastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Levocabastine.
LevocetirizineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Azelastine is combined with Levocetirizine.
LevodopaLevodopa may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
LevodopaThe risk or severity of adverse effects can be increased when Azelastine is combined with Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Azelastine.
Levomethadyl AcetateLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Azelastine is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Azelastine is combined with Levomilnacipran.
LevorphanolLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
LevorphanolThe risk or severity of adverse effects can be increased when Azelastine is combined with Levorphanol.
LidocaineLidocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
LidocaineThe risk or severity of adverse effects can be increased when Azelastine is combined with Lidocaine.
LimaprostLimaprost may increase the antiplatelet activities of Azelastine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Azelastine.
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Azelastine.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Azelastine.
LithiumLithium may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
LithiumThe risk or severity of adverse effects can be increased when Azelastine is combined with Lithium.
LofentanilLofentanil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
LofentanilThe risk or severity of adverse effects can be increased when Azelastine is combined with Lofentanil.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Azelastine.
LopinavirThe metabolism of Azelastine can be decreased when combined with Lopinavir.
LoratadineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
LoratadineThe risk or severity of adverse effects can be increased when Azelastine is combined with Loratadine.
LorazepamLorazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
LorazepamThe risk or severity of adverse effects can be increased when Azelastine is combined with Lorazepam.
LorcaserinThe metabolism of Azelastine can be decreased when combined with Lorcaserin.
LornoxicamThe risk or severity of adverse effects can be increased when Azelastine is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Azelastine.
LosartanThe serum concentration of Losartan can be increased when it is combined with Azelastine.
LovastatinThe metabolism of Azelastine can be decreased when combined with Lovastatin.
LoxapineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
LoxapineThe risk or severity of adverse effects can be increased when Azelastine is combined with Loxapine.
LoxoprofenThe risk or severity of adverse effects can be increased when Azelastine is combined with Loxoprofen.
Lu AA21004Lu AA21004 may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Lu AA21004The risk or severity of adverse effects can be increased when Azelastine is combined with Lu AA21004.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Azelastine.
LuliconazoleThe serum concentration of Azelastine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Azelastine can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Azelastine can be decreased when combined with Lumefantrine.
LumiracoxibThe risk or severity of adverse effects can be increased when Azelastine is combined with Lumiracoxib.
LurasidoneLurasidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
LurasidoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Lurasidone.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Azelastine is combined with Magnesium salicylate.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Azelastine is combined with Magnesium Sulfate.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Azelastine.
MaprotilineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
MaprotilineThe risk or severity of adverse effects can be increased when Azelastine is combined with Maprotiline.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Azelastine.
MeclizineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
MeclizineThe risk or severity of adverse effects can be increased when Azelastine is combined with Meclizine.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Azelastine.
MedetomidineMedetomidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
MedetomidineThe risk or severity of adverse effects can be increased when Azelastine is combined with Medetomidine.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Azelastine.
MelatoninMelatonin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
MelatoninThe risk or severity of adverse effects can be increased when Azelastine is combined with Melatonin.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Azelastine.
MelperoneMelperone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
MelperoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Melperone.
MephentermineMephentermine may decrease the sedative activities of Azelastine.
MepivacaineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
MepivacaineThe risk or severity of adverse effects can be increased when Azelastine is combined with Mepivacaine.
MeprobamateMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
MeprobamateThe risk or severity of adverse effects can be increased when Azelastine is combined with Meprobamate.
MesalazineAzelastine may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Azelastine.
MesoridazineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
MesoridazineThe risk or severity of adverse effects can be increased when Azelastine is combined with Mesoridazine.
MetamizoleThe risk or severity of adverse effects can be increased when Azelastine is combined with Metamizole.
MetaxaloneMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
MetaxaloneThe risk or severity of adverse effects can be increased when Azelastine is combined with Metaxalone.
MethadoneMethadone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
MethadoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Methadone.
Methadyl AcetateMethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Azelastine is combined with Methadyl Acetate.
MethamphetamineMethamphetamine may decrease the sedative activities of Azelastine.
MethapyrileneMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
MethapyrileneThe risk or severity of adverse effects can be increased when Azelastine is combined with Methapyrilene.
MethaqualoneMethaqualone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
MethaqualoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Methaqualone.
MethocarbamolMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
MethocarbamolThe risk or severity of adverse effects can be increased when Azelastine is combined with Methocarbamol.
MethohexitalMethohexital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
MethohexitalThe risk or severity of adverse effects can be increased when Azelastine is combined with Methohexital.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Azelastine.
MethotrimeprazineMethotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Azelastine is combined with Methotrimeprazine.
MethoxyfluraneMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Azelastine is combined with Methoxyflurane.
MethsuximideMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
MethsuximideThe risk or severity of adverse effects can be increased when Azelastine is combined with Methsuximide.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Azelastine.
MethylphenobarbitalMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Azelastine is combined with Methylphenobarbital.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Azelastine.
MetipranololAzelastine may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Azelastine.
MetoprololAzelastine may decrease the antihypertensive activities of Metoprolol.
MetoprololThe metabolism of Azelastine can be decreased when combined with Metoprolol.
MetrizamideAzelastine may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MetyrosineAzelastine may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Azelastine can be decreased when combined with Mexiletine.
MidazolamMidazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Azelastine.
MifepristoneThe metabolism of Azelastine can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Azelastine is combined with Milnacipran.
MilrinoneMilrinone may increase the antiplatelet activities of Azelastine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Azelastine.
MirabegronThe metabolism of Azelastine can be decreased when combined with Mirabegron.
MirtazapineAzelastine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Azelastine.
MitotaneThe serum concentration of Azelastine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Azelastine.
MoclobemideThe metabolism of Azelastine can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Azelastine can be decreased when it is combined with Modafinil.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Azelastine.
MolindoneMolindone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
MolindoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Molindone.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Azelastine.
MorphineMorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
MorphineThe serum concentration of Morphine can be increased when it is combined with Azelastine.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Azelastine.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Azelastine is combined with Mycophenolic acid.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
NabiloneThe risk or severity of adverse effects can be increased when Azelastine is combined with Nabilone.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Azelastine.
NadololAzelastine may decrease the antihypertensive activities of Nadolol.
NadroparinAzelastine may increase the anticoagulant activities of Nadroparin.
NafcillinThe serum concentration of Azelastine can be decreased when it is combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Azelastine.
NalbuphineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
NalbuphineThe risk or severity of adverse effects can be increased when Azelastine is combined with Nalbuphine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Azelastine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Azelastine.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Azelastine.
NCX 4016The risk or severity of adverse effects can be increased when Azelastine is combined with NCX 4016.
NefazodoneThe metabolism of Azelastine can be decreased when combined with Nefazodone.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Azelastine.
NelfinavirThe metabolism of Azelastine can be decreased when combined with Nelfinavir.
NeomycinAzelastine may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Azelastine is combined with Nepafenac.
NetilmicinAzelastine may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
NetupitantThe serum concentration of Azelastine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Azelastine can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Azelastine.
NicardipineThe metabolism of Azelastine can be decreased when combined with Nicardipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Azelastine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Azelastine is combined with Niflumic Acid.
NilotinibThe metabolism of Azelastine can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Azelastine.
NimesulideThe risk or severity of adverse effects can be increased when Azelastine is combined with Nimesulide.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Azelastine.
NitrazepamNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
NitrazepamThe risk or severity of adverse effects can be increased when Azelastine is combined with Nitrazepam.
Nitrous oxideNitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Azelastine is combined with Nitrous oxide.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Azelastine.
NormethadoneNormethadone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
NormethadoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Normethadone.
NortriptylineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
NortriptylineThe risk or severity of adverse effects can be increased when Azelastine is combined with Nortriptyline.
ObinutuzumabThe risk or severity of adverse effects can be increased when Azelastine is combined with Obinutuzumab.
OlanzapineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
OlanzapineThe risk or severity of adverse effects can be increased when Azelastine is combined with Olanzapine.
OlaparibThe metabolism of Azelastine can be decreased when combined with Olaparib.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Azelastine.
OlopatadineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
OlopatadineThe risk or severity of adverse effects can be increased when Azelastine is combined with Olopatadine.
OlsalazineAzelastine may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Azelastine.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Azelastine is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Azelastine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Azelastine.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Azelastine.
OmeprazoleThe metabolism of Azelastine can be decreased when combined with Omeprazole.
OndansetronOndansetron may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
OndansetronThe risk or severity of adverse effects can be increased when Azelastine is combined with Ondansetron.
OpiumOpium may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
OpiumThe risk or severity of adverse effects can be increased when Azelastine is combined with Opium.
OrgoteinThe risk or severity of adverse effects can be increased when Azelastine is combined with Orgotein.
OrphenadrineAzelastine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OsanetantOsanetant may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
OsanetantThe risk or severity of adverse effects can be increased when Azelastine is combined with Osanetant.
OsimertinibThe serum concentration of Azelastine can be increased when it is combined with Osimertinib.
OtamixabanAzelastine may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Azelastine is combined with Oxaprozin.
OxazepamOxazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
OxazepamThe risk or severity of adverse effects can be increased when Azelastine is combined with Oxazepam.
OxprenololOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
OxprenololAzelastine may decrease the antihypertensive activities of Oxprenolol.
OxybuprocaineOxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Azelastine is combined with Oxybuprocaine.
OxycodoneOxycodone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
OxycodoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Oxycodone.
OxymorphoneOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
OxymorphoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Oxymorphone.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Oxyphenbutazone.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Azelastine.
PalbociclibThe serum concentration of Azelastine can be increased when it is combined with Palbociclib.
PaliperidonePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
PaliperidoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Paliperidone.
PamidronateThe risk or severity of adverse effects can be increased when Azelastine is combined with Pamidronate.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Azelastine.
PanobinostatThe metabolism of Azelastine can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Azelastine can be decreased when combined with Pantoprazole.
ParaldehydeAzelastine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParecoxibThe risk or severity of adverse effects can be increased when Azelastine is combined with Parecoxib.
ParnaparinAzelastine may increase the anticoagulant activities of Parnaparin.
ParomomycinAzelastine may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
ParoxetineThe risk or severity of adverse effects can be increased when Azelastine is combined with Paroxetine.
ParoxetineThe metabolism of Azelastine can be decreased when combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Azelastine.
Peginterferon alfa-2bThe serum concentration of Azelastine can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololAzelastine may decrease the antihypertensive activities of Penbutolol.
PentazocinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
PentazocineThe risk or severity of adverse effects can be increased when Azelastine is combined with Pentazocine.
PentobarbitalPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
PentobarbitalThe risk or severity of adverse effects can be increased when Azelastine is combined with Pentobarbital.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Azelastine.
Pentosan PolysulfateAzelastine may increase the anticoagulant activities of Pentosan Polysulfate.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Azelastine.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
PerampanelThe risk or severity of adverse effects can be increased when Azelastine is combined with Perampanel.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Azelastine.
PerospironePerospirone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
PerospironeThe risk or severity of adverse effects can be increased when Azelastine is combined with Perospirone.
PerphenazinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
PerphenazineThe risk or severity of adverse effects can be increased when Azelastine is combined with Perphenazine.
PethidinePethidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
PethidineThe risk or severity of adverse effects can be increased when Azelastine is combined with Pethidine.
PhenindioneAzelastine may increase the anticoagulant activities of Phenindione.
PhenobarbitalPhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Azelastine.
PhenoxyethanolPhenoxyethanol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Azelastine is combined with Phenoxyethanol.
PhenprocoumonAzelastine may increase the anticoagulant activities of Phenprocoumon.
PhenterminePhentermine may decrease the sedative activities of Azelastine.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Azelastine.
PhenytoinPhenytoin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Azelastine.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Azelastine.
PimozidePimozide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
PimozideThe risk or severity of adverse effects can be increased when Azelastine is combined with Pimozide.
PindololAzelastine may decrease the antihypertensive activities of Pindolol.
PioglitazoneThe metabolism of Azelastine can be decreased when combined with Pioglitazone.
PipamperonePipamperone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
PipamperoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Pipamperone.
PipotiazinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
PipotiazineThe risk or severity of adverse effects can be increased when Azelastine is combined with Pipotiazine.
PiretanideAzelastine may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Azelastine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Azelastine.
PizotifenPizotifen may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
PizotifenThe risk or severity of adverse effects can be increased when Azelastine is combined with Pizotifen.
PlasminAzelastine may increase the anticoagulant activities of Plasmin.
PlicamycinAzelastine may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Azelastine.
PomalidomidePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Azelastine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Azelastine.
PosaconazoleThe metabolism of Azelastine can be decreased when combined with Posaconazole.
PractololAzelastine may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Azelastine.
PramipexoleAzelastine may increase the sedative activities of Pramipexole.
PramocainePramocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
PramocaineThe risk or severity of adverse effects can be increased when Azelastine is combined with Pramocaine.
PrasugrelAzelastine may increase the anticoagulant activities of Prasugrel.
PrasugrelPrasugrel may increase the antiplatelet activities of Azelastine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Azelastine.
PrazepamPrazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
PrazepamThe risk or severity of adverse effects can be increased when Azelastine is combined with Prazepam.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Azelastine.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Azelastine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Azelastine.
PregabalinPregabalin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
PregabalinThe risk or severity of adverse effects can be increased when Azelastine is combined with Pregabalin.
PrilocainePrilocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
PrilocaineThe risk or severity of adverse effects can be increased when Azelastine is combined with Prilocaine.
PrimidonePrimidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
PrimidoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Primidone.
ProbenecidThe serum concentration of Azelastine can be increased when it is combined with Probenecid.
ProcaineProcaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ProcaineThe risk or severity of adverse effects can be increased when Azelastine is combined with Procaine.
ProchlorperazineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Azelastine is combined with Prochlorperazine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Azelastine.
PromazinePromazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
PromazineThe risk or severity of adverse effects can be increased when Azelastine is combined with Promazine.
PromethazinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
PromethazineThe risk or severity of adverse effects can be increased when Azelastine is combined with Promethazine.
PropacetamolThe risk or severity of adverse effects can be increased when Azelastine is combined with Propacetamol.
ProparacaineProparacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ProparacaineThe risk or severity of adverse effects can be increased when Azelastine is combined with Proparacaine.
PropofolPropofol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
PropofolThe risk or severity of adverse effects can be increased when Azelastine is combined with Propofol.
PropoxycainePropoxycaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
PropoxycaineThe risk or severity of adverse effects can be increased when Azelastine is combined with Propoxycaine.
PropranololAzelastine may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Azelastine.
Protein CAzelastine may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeAzelastine may increase the anticoagulant activities of Protocatechualdehyde.
ProtriptylineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ProtriptylineThe risk or severity of adverse effects can be increased when Azelastine is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Azelastine.
PSD502PSD502 may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
PSD502The risk or severity of adverse effects can be increased when Azelastine is combined with PSD502.
PTC299The risk or severity of adverse effects can be increased when Azelastine is combined with PTC299.
PuromycinAzelastine may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
PyrimethamineThe metabolism of Azelastine can be decreased when combined with Pyrimethamine.
QuazepamQuazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
QuazepamThe risk or severity of adverse effects can be increased when Azelastine is combined with Quazepam.
QuetiapineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Azelastine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Azelastine.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Azelastine.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Azelastine.
QuinidineThe metabolism of Azelastine can be decreased when combined with Quinidine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Azelastine.
QuinineThe metabolism of Azelastine can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Azelastine can be decreased when combined with Rabeprazole.
RamelteonRamelteon may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
RamelteonThe risk or severity of adverse effects can be increased when Azelastine is combined with Ramelteon.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Azelastine.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Azelastine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Azelastine.
RanolazineThe metabolism of Azelastine can be decreased when combined with Ranolazine.
RemifentanilRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
RemifentanilThe risk or severity of adverse effects can be increased when Azelastine is combined with Remifentanil.
RemoxiprideRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
RemoxiprideThe risk or severity of adverse effects can be increased when Azelastine is combined with Remoxipride.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Azelastine.
ReserpineReserpine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Azelastine.
ResveratrolThe risk or severity of adverse effects can be increased when Azelastine is combined with Resveratrol.
ReteplaseAzelastine may increase the anticoagulant activities of Reteplase.
ReviparinAzelastine may increase the anticoagulant activities of Reviparin.
RibostamycinAzelastine may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RidogrelAzelastine may increase the antiplatelet activities of Ridogrel.
RifabutinThe metabolism of Azelastine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Azelastine can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Azelastine.
RifapentineThe metabolism of Azelastine can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Azelastine.
RisedronateThe risk or severity of adverse effects can be increased when Azelastine is combined with Risedronate.
RisperidoneRisperidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Azelastine.
RitonavirThe metabolism of Azelastine can be decreased when combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Azelastine.
RivaroxabanAzelastine may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Azelastine.
RolapitantThe metabolism of Azelastine can be decreased when combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Azelastine.
RomifidineRomifidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
RomifidineThe risk or severity of adverse effects can be increased when Azelastine is combined with Romifidine.
RopiniroleAzelastine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Azelastine can be decreased when combined with Ropinirole.
RopivacaineRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
RopivacaineThe risk or severity of adverse effects can be increased when Azelastine is combined with Ropivacaine.
RosiglitazoneAzelastine may increase the anticoagulant activities of Rosiglitazone.
RosiglitazoneThe metabolism of Azelastine can be decreased when combined with Rosiglitazone.
RotigotineAzelastine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Azelastine.
S-EthylisothioureaS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Azelastine is combined with S-Ethylisothiourea.
SalicylamideThe risk or severity of adverse effects can be increased when Azelastine is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Azelastine.
SalsalateThe risk or severity of adverse effects can be increased when Azelastine is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Azelastine.
SaquinavirThe metabolism of Azelastine can be decreased when combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Azelastine.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Azelastine.
SCH-530348Azelastine may increase the antiplatelet activities of SCH-530348.
ScopolamineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ScopolamineThe risk or severity of adverse effects can be increased when Azelastine is combined with Scopolamine.
SecobarbitalSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
SecobarbitalThe risk or severity of adverse effects can be increased when Azelastine is combined with Secobarbital.
SelexipagAzelastine may increase the anticoagulant activities of Selexipag.
SeratrodastThe risk or severity of adverse effects can be increased when Azelastine is combined with Seratrodast.
SertindoleSertindole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
SertindoleThe risk or severity of adverse effects can be increased when Azelastine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Azelastine is combined with Sertraline.
SertralineThe metabolism of Azelastine can be decreased when combined with Sertraline.
SevofluraneSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
SevofluraneThe risk or severity of adverse effects can be increased when Azelastine is combined with Sevoflurane.
SildenafilThe metabolism of Azelastine can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Azelastine.
SiltuximabThe serum concentration of Azelastine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Azelastine can be increased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Azelastine.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Azelastine is combined with Sodium oxybate.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Azelastine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Azelastine.
SorafenibThe metabolism of Azelastine can be decreased when combined with Sorafenib.
SotalolAzelastine may decrease the antihypertensive activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Azelastine.
SpectinomycinAzelastine may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Azelastine.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Azelastine.
SpironolactoneAzelastine may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Azelastine is combined with SRT501.
St. John's WortThe serum concentration of Azelastine can be decreased when it is combined with St. John's Wort.
StiripentolStiripentol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
StiripentolThe risk or severity of adverse effects can be increased when Azelastine is combined with Stiripentol.
StreptokinaseAzelastine may increase the anticoagulant activities of Streptokinase.
StreptomycinAzelastine may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinAzelastine may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SufentanilSufentanil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
SufentanilThe risk or severity of adverse effects can be increased when Azelastine is combined with Sufentanil.
SulfadiazineThe metabolism of Azelastine can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Azelastine can be decreased when combined with Sulfamethoxazole.
SulfasalazineAzelastine may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Azelastine.
SulfisoxazoleThe metabolism of Azelastine can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Azelastine.
SulodexideAzelastine may increase the anticoagulant activities of Sulodexide.
SulpirideSulpiride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
SulpirideThe risk or severity of adverse effects can be increased when Azelastine is combined with Sulpiride.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Azelastine.
SuvorexantSuvorexant may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
SuvorexantThe risk or severity of adverse effects can be increased when Azelastine is combined with Suvorexant.
TacrolimusAzelastine may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Azelastine.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Azelastine.
TamoxifenThe metabolism of Azelastine can be decreased when combined with Tamoxifen.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
TapentadolThe risk or severity of adverse effects can be increased when Azelastine is combined with Tapentadol.
TasimelteonTasimelteon may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
TasimelteonThe risk or severity of adverse effects can be increased when Azelastine is combined with Tasimelteon.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Azelastine.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Azelastine.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Azelastine is combined with Technetium Tc-99m Medronate.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Azelastine.
TelaprevirThe metabolism of Azelastine can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Azelastine.
TelithromycinThe metabolism of Azelastine can be decreased when combined with Telithromycin.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Azelastine.
TemazepamTemazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
TemazepamThe risk or severity of adverse effects can be increased when Azelastine is combined with Temazepam.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Azelastine.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Azelastine.
TenecteplaseAzelastine may increase the anticoagulant activities of Tenecteplase.
TenofovirThe risk or severity of adverse effects can be increased when Azelastine is combined with Tenofovir.
TenofovirThe metabolism of Azelastine can be decreased when combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Azelastine.
TepoxalinThe risk or severity of adverse effects can be increased when Azelastine is combined with Tepoxalin.
TerbinafineThe metabolism of Azelastine can be decreased when combined with Terbinafine.
TeriflunomideThe serum concentration of Azelastine can be decreased when it is combined with Teriflunomide.
TeriflunomideThe risk or severity of adverse effects can be increased when Azelastine is combined with Teriflunomide.
TesmilifeneAzelastine may increase the antiplatelet activities of Tesmilifene.
TetrabenazineTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
TetrabenazineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tetrabenazine.
TetracaineTetracaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
TetracaineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tetracaine.
TetrodotoxinTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Azelastine is combined with Tetrodotoxin.
ThalidomideAzelastine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TheophyllineThe metabolism of Azelastine can be decreased when combined with Theophylline.
ThiamylalThiamylal may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ThiamylalThe risk or severity of adverse effects can be increased when Azelastine is combined with Thiamylal.
ThiopentalThiopental may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ThiopentalThe risk or severity of adverse effects can be increased when Azelastine is combined with Thiopental.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Azelastine.
ThioridazineThioridazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ThiothixeneThiothixene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ThiothixeneThe risk or severity of adverse effects can be increased when Azelastine is combined with Thiothixene.
TiagabineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
TiagabineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tiagabine.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Azelastine is combined with Tiaprofenic acid.
TicagrelorAzelastine may increase the anticoagulant activities of Ticagrelor.
TicagrelorThe metabolism of Azelastine can be decreased when combined with Ticagrelor.
TiclopidineAzelastine may increase the anticoagulant activities of Ticlopidine.
TiclopidineThe metabolism of Azelastine can be decreased when combined with Ticlopidine.
TiletamineTiletamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
TiletamineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tiletamine.
TiludronateThe risk or severity of adverse effects can be increased when Azelastine is combined with Tiludronate.
TimololAzelastine may decrease the antihypertensive activities of Timolol.
TinzaparinAzelastine may increase the anticoagulant activities of Tinzaparin.
TipranavirTipranavir may increase the antiplatelet activities of Azelastine.
TirofibanAzelastine may increase the anticoagulant activities of Tirofiban.
TirofibanTirofiban may increase the antiplatelet activities of Azelastine.
TizanidineTizanidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
TizanidineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tizanidine.
TobramycinAzelastine may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TocilizumabThe serum concentration of Azelastine can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Azelastine can be decreased when combined with Tolbutamide.
TolcaponeTolcapone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
TolcaponeThe risk or severity of adverse effects can be increased when Azelastine is combined with Tolcapone.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Azelastine is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Azelastine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Azelastine.
TopiramateTopiramate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
TopiramateThe risk or severity of adverse effects can be increased when Azelastine is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Azelastine.
TorasemideAzelastine may decrease the diuretic activities of Torasemide.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Azelastine.
TositumomabThe risk or severity of adverse effects can be increased when Azelastine is combined with Tositumomab.
TramadolTramadol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
TramadolThe risk or severity of adverse effects can be increased when Azelastine is combined with Tramadol.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Azelastine.
TranilastThe risk or severity of adverse effects can be increased when Azelastine is combined with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Azelastine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
TranylcypromineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tranylcypromine.
TrapidilAzelastine may increase the antiplatelet activities of Trapidil.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Azelastine.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Azelastine.
TrazodoneTrazodone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
TrazodoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Trazodone.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Azelastine.
TreprostinilAzelastine may increase the anticoagulant activities of Treprostinil.
TriamtereneAzelastine may decrease the antihypertensive activities of Triamterene.
TriazolamTriazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
TriazolamThe risk or severity of adverse effects can be increased when Azelastine is combined with Triazolam.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Azelastine.
TrifluoperazineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Azelastine is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
TriflupromazineThe risk or severity of adverse effects can be increased when Azelastine is combined with Triflupromazine.
TriflusalAzelastine may increase the anticoagulant activities of Triflusal.
TriflusalTriflusal may increase the antiplatelet activities of Azelastine.
TrimethoprimThe metabolism of Azelastine can be decreased when combined with Trimethoprim.
TrimipramineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
TrimipramineThe risk or severity of adverse effects can be increased when Azelastine is combined with Trimipramine.
TriprolidineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
TriprolidineThe risk or severity of adverse effects can be increased when Azelastine is combined with Triprolidine.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Azelastine is combined with Trisalicylate-choline.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Azelastine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Azelastine.
UrokinaseAzelastine may increase the anticoagulant activities of Urokinase.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Azelastine.
Valproic AcidValproic Acid may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Valproic AcidThe risk or severity of adverse effects can be increased when Azelastine is combined with Valproic Acid.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Azelastine.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Azelastine.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Azelastine.
VemurafenibThe serum concentration of Azelastine can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Azelastine can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Azelastine.
VerapamilThe metabolism of Azelastine can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Azelastine.
VigabatrinVigabatrin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
VigabatrinThe risk or severity of adverse effects can be increased when Azelastine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Vilazodone.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Azelastine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Azelastine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Azelastine.
Vitamin EVitamin E may increase the antiplatelet activities of Azelastine.
VorapaxarAzelastine may increase the anticoagulant activities of Vorapaxar.
VorapaxarVorapaxar may increase the antiplatelet activities of Azelastine.
VoriconazoleThe metabolism of Azelastine can be decreased when combined with Voriconazole.
VortioxetineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
VortioxetineThe risk or severity of adverse effects can be increased when Azelastine is combined with Vortioxetine.
WarfarinAzelastine may increase the anticoagulant activities of Warfarin.
XimelagatranAzelastine may increase the anticoagulant activities of Ximelagatran.
XylazineXylazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
XylazineThe risk or severity of adverse effects can be increased when Azelastine is combined with Xylazine.
ZafirlukastThe metabolism of Azelastine can be decreased when combined with Zafirlukast.
ZaleplonZaleplon may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ZaleplonThe risk or severity of adverse effects can be increased when Azelastine is combined with Zaleplon.
ZaltoprofenThe risk or severity of adverse effects can be increased when Azelastine is combined with Zaltoprofen.
ZiconotideZiconotide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ZiconotideThe risk or severity of adverse effects can be increased when Azelastine is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Azelastine.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Azelastine.
ZimelidineThe risk or severity of adverse effects can be increased when Azelastine is combined with Zimelidine.
ZiprasidoneZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Ziprasidone.
ZolazepamZolazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ZolazepamThe risk or severity of adverse effects can be increased when Azelastine is combined with Zolazepam.
Zoledronic acidThe risk or severity of adverse effects can be increased when Azelastine is combined with Zoledronic acid.
ZolpidemZolpidem may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ZolpidemThe risk or severity of adverse effects can be increased when Azelastine is combined with Zolpidem.
ZomepiracThe risk or severity of adverse effects can be increased when Azelastine is combined with Zomepirac.
ZonisamideZonisamide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ZonisamideThe risk or severity of adverse effects can be increased when Azelastine is combined with Zonisamide.
ZopicloneZopiclone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ZopicloneThe risk or severity of adverse effects can be increased when Azelastine is combined with Zopiclone.
ZotepineZotepine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ZotepineThe risk or severity of adverse effects can be increased when Azelastine is combined with Zotepine.
ZuclopenthixolZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Azelastine is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Casale TB: The interaction of azelastine with human lung histamine H1, beta, and muscarinic receptor-binding sites. J Allergy Clin Immunol. 1989 Apr;83(4):771-6. [PubMed:2540229 ]
  2. Conde Hernandez DJ, Palma Aqilar JL, Delgado Romero J: Comparison of azelastine nasal spray and oral ebastine in treating seasonal allergic rhinitis. Curr Med Res Opin. 1995;13(6):299-304. [PubMed:8829888 ]
  3. Antepara I, Jauregui I, Basomba A, Cadahia A, Feo F, Garcia JJ, Gonzalo MA, Luna I, Rubio M, Vazquez M: [Investigation of the efficacy and tolerability of azelastine nasal spray versus ebastine tablets in patients with seasonal allergic rhinitis]. Allergol Immunopathol (Madr). 1998 Jan-Feb;26(1):9-16. [PubMed:9585822 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Horak F: Effectiveness of twice daily azelastine nasal spray in patients with seasonal allergic rhinitis. Ther Clin Risk Manag. 2008 Oct;4(5):1009-22. [PubMed:19209282 ]
  6. Bernstein JA: Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. Curr Med Res Opin. 2007 Oct;23(10):2441-52. [PubMed:17723160 ]
  7. Golden SJ, Craig TJ: Efficacy and safety of azelastine nasal spray for the treatment of allergic rhinitis. J Am Osteopath Assoc. 1999 Jul;99(7 Suppl):S7-12. [PubMed:10478514 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Katoh M, Nakajima M, Yamazaki H, Yokoi T: Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci. 2001 Feb;12(4):505-13. [PubMed:11231118 ]
  2. Hu YP, Robert J: Azelastine and flezelastine as reversing agents of multidrug resistance: pharmacological and molecular studies. Biochem Pharmacol. 1995 Jul 17;50(2):169-75. [PubMed:7632160 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 25, 2016 02:24